FIGURES LOOK GOOD ON LAST MONTHLYEXPANSION PROGRESS WELL UNDERWAY.CAN ONLY IMPROVE.BEING HURT BY TAX SELLERS. WILL SEE IT BACK INTO THE 20-30CENT RANGE IN NEXT FEW MONTHS
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%